We are live on ! Find out more
OKYO

OKYO Pharma

7 hedge funds and large institutions have $1.18M invested in OKYO Pharma in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more funds holding

Funds holding: 67 (+1)

16% more capital invested

Capital invested by funds: $1.02M → $1.18M (+$158K)

0.07% more ownership

Funds ownership: 2.95%3.03% (+0.07%)

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.09%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
2
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change
Change in
Stake
Barclays
1
Barclays
United Kingdom
$1.11M
Citadel Advisors
2
Citadel Advisors
Florida
$23.8K +$6.28K +5,853 +39%
Renaissance Technologies
3
Renaissance Technologies
New York
$19K +$17.7K +16,500 New
Cerity Partners
4
Cerity Partners
New York
$14.7K
Geode Capital Management
5
Geode Capital Management
Massachusetts
$13.9K
UBS Group
6
UBS Group
Switzerland
$3.45K +$2.65K +2,473 +471%
CA
7
Continuum Advisory
Idaho
$58

OKYO Hedge Fund Activity: Q4 2024 in Review

7 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in OKYO Pharma (OKYO) for Q4 2024, worth a combined $1.18M — up 16% from $1.02M a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new OKYO positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $17.7K.

  • 7 institutional investors held OKYO Pharma (OKYO) as of Q4 2024, up from 6 in Q3 2024.
  • Funds reported $1.18M of OKYO Pharma stock for Q4 2024, up 16% quarter-over-quarter.
  • 1 fund opened new OKYO Pharma positions in Q4 2024 and 0 closed out, a net change of +1 holder.
  • The largest OKYO Pharma buyer in Q4 2024 was Renaissance Technologies, an estimated $17.7K added.

Based on aggregated 13F filings for Q4 2024.